ExoOne Bio Co., Ltd. (ExoOne Bio) was established in December 2020. Professor Tzou-Yien Lin is the chairman and CEO and a repute pediatrician. He served in several important positions, including former minister of Taiwan FDA, Chairman of National Health Research Institute, President of The Infectious Diseases Society of Taiwan, and President of Taiwan Pediatric Association. ExoOne Bio focuses the research and development of exosomes and their application in degenerative diseases. The vision of the company is to become world’s leading biotech center in anti-aging and rejuvenation and the mission is to apply prime exosome products to treat degenerative diseases and to extend health lifespan. ExoOne Bio’s exosome application in new drug is regarded an index project by CDE (Center for Drug Evaluation, Taiwan). CDE will support ExoOne Bio in exosome development and provide review guidance and submission requirement.
2020 | ExoOne Bio Co., Ltd. established in Linkou, New Taipei City |
2021 | ExoOne Bio’s exosome new drug development selected by CDE as an Index Project |
2021 | Established an independent in-house exosome research & development Lab. |
2021 | Sign academia collaboration agreement on research & development with several institutes |
2022 | ExoOne Bio signs CDMO agreement with Taiwan Bio Therapeutics Co., Ltd. |
2022 | Sign collaboration agreement for new drug pre-clinical development with several institutes |
2022 | Cosmetic functional assays completed |
2022 | Cosmetic human clinical studies ongoing |
2022 | Cosmetic data submitted for publication |
2023 | Exosome biodistribution data completed |
2023 | Approved by Ministry of Economic Affairs as a qualified biotech company |
2023 | Fund raising to NT$120Mil. |
2023 | Exosome functional studies in osteoarthritis、degenerative eye diseases、& anti-aging completed |
2023 | ExoHair Essence study ongoing |